virtual.nov2024.dermatologyweek.com Open in urlscan Pro
45.60.34.19  Public Scan

Form analysis
1 forms found in the DOM

POST /media/improving-outcomes-patients-psoriasis-and-psoriatic-arthritis-focus-interleukin-inhibitors?hmpid=amVtYXJ0aW5Ab2Noc25lci5vcmc%3D&utm_medium=email&utm_source=OG_DermWeek&utm_content=2451792470

<form class="sessionpoll" data-drupal-selector="sessionpoll"
  action="/media/improving-outcomes-patients-psoriasis-and-psoriatic-arthritis-focus-interleukin-inhibitors?hmpid=amVtYXJ0aW5Ab2Noc25lci5vcmc%3D&amp;utm_medium=email&amp;utm_source=OG_DermWeek&amp;utm_content=2451792470" method="post"
  id="sessionpoll" accept-charset="UTF-8">
  <input autocomplete="off" data-drupal-selector="form-l1-6hgxqs2q2aa-t-mpr5lr4g6d6s-dtnacing08mna" type="hidden" name="form_build_id" value="form-L1-6HGXqs2q2Aa-t_mPr5lR4G6d6S-DtNacIng08mNA">
  <input data-drupal-selector="edit-sessionpoll" type="hidden" name="form_id" value="SessionPoll">
</form>

Text Content

Skip to main content
X
November 13-16, 2024
Return to Site
Arcutis
Dermatology Nurses’ Association
Lilly
National Alopecia Areata Foundation
National Eczema Association
National Psoriasis Foundation
National Rosacea Society
Pfizer
Regeneron
Sanofi | Regeneron
Skin Cancer Foundation
Skin of Color Society



If you're having problems viewing this page, click here to refresh.

Click here to view other sessions »


IMPROVING OUTCOMES IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS: A FOCUS
ON INTERLEUKIN INHIBITORS

On-Demand Upgrade

This session has ended and can only be viewed with our Plus or Premium Plus
Packages. Click the “On-Demand Upgrade” button to upgrade your access.

• Plus Package: Includes 30 Days of On-Demand streaming, from 11/19/2024 –
12/19/2024.
• Premium Plus Package: Includes 90 Days of On-Demand streaming, from 11/19/2024
– 02/19/2025.

To prevent irreversible disease progression and loss of function, early
diagnosis of psoriasis (PsO) and psoriatic arthritis (PsA) is essential.
However, these conditions continue to be underrecognized and undertreated. In
this informative session, experts will examine the burden and pathogenesis of
PsO and PsA, while also evaluating the role of interleukin (IL) inhibitors in
managing these diseases. In addition, attendees will learn about effective
collaborative treatment strategies and evidence-based care that can best serve
patients with PsO and PsA.


LEARNING OBJECTIVES:

 * Assess the burden of PsO and PsA and the impact of underrecognition and
   undertreatment on patients
 * Describe the pathogenesis of PsO and PsA, as well as the role of the
   IL-23/Th17 and Th1 pathways in the treatment of these conditions
 * Evaluate the clinical rationale and safety/efficacy data of IL inhibitors
   approved/under investigation for the treatment of PsO and PsA
 * Implement collaborative treatment strategies for patients with PsO and PsA
   which consider IL inhibitors, where appropriate, and evidence-based care

Supported by an independent educational grant from Janssen Biotech, Inc.,
administered by Janssen Scientific Affairs, LLC.

 

DOWNLOAD

Session Slides_Merola

MODERATOR

Joel
 Gelfand, MD MSCE

Professor of Dermatology and Epidemiology

University of Pennsylvania Perelman School of Medicine

View Bio
Joel
 Gelfand, MD MSCE

Professor of Dermatology and Epidemiology

University of Pennsylvania Perelman School of Medicine

Joel M. Gelfand MD MSCE is the James J. Leyden Professor (with tenure) of
Dermatology and Epidemiology, Director (founding) of the Center for Clinical
Sciences in Dermatology, and Director of the Psoriasis and Phototherapy
Treatment Center at the University of Pennsylvania Perelman School of Medicine.
He is a nationally and internationally recognized expert in psoriasis, clinical
epidemiology, drug safety, and clinical trials. Dr. Gelfand is the author of
over 330 scientific publications cited over 38,000 times (H index 99). He is
Deputy Editor for Clinical Research of the Journal Investigative Dermatology. He
is the recipient of the American College of Epidemiology 2023 Outstanding
Contributions Award, the American Skin Association’s Psoriasis Achievement
Award, the Lady Barbara Colyton’s Award for Autoimmune research, the National
Psoriasis Foundation’s scientific achievement award, the American
Dermatoepidemiology Network’s Founders award, and is an elected member of the
American Society for Clinical Investigation. He is a member of the Board of
Directors for the International Psoriasis Council and the Medical Dermatology
Society. He has given over 10 named lectureships and keynote addresses. He has
received grants from NIH, FDA, PCORI, and the National Psoriasis Foundation to
support his independent research program. His research redefined psoriasis as a
systemic inflammatory disease that enhances the risk of cardiovascular events
and premature mortality resulting in changes in standard of care guidelines. The
overarching goal of his research and clinical practice is to improve psoriasis
patient outcomes in the skin and joints, while lowering the risk of diabetes, CV
disease and mortality.


PRESENTATIONS

Hot Topics in Dermatology: 2023-2024
Wednesday, Nov 13, 2024, 8 - 9:05am EST
Edit Joel

FACULTY

Joseph
 Merola, MD, MMSc, FAAD, FACR

Chair

UT Southwestern Medical Center

View Bio
Joseph
 Merola, MD, MMSc, FAAD, FACR

Chair

UT Southwestern Medical Center

Joseph F. Merola, MD, MMSc is Chair of Dermatology at UT Southwestern Medical
Center in Dallas, TX; he is Professor of Dermatology, Medicine and Rheumatology
at UTSW and the Peter O’Donnell Jr School of Public Health. He holds the Mary
Kay Distinguished Chair in Dermatology. Dr. Merola is board-certified in
Dermatology, Internal Medicine, and Rheumatology. He earned his medical degree
at the NYU School of Medicine and his Masters at Harvard Medical School. He
completed an internship in Internal Medicine at the Hospital of the University
of Pennsylvania, residency in Dermatology at NYU Medical Center. He continued
with a residency in Internal Medicine and a fellowship in Rheumatology at the
Brigham and Women’s Hospital / Harvard Medical School in Boston. He was elected
to the Board of Directors of the American Academy of Dermatology, is the
Founding President of PPACMAN, is on the Scientific and Medical Boards of the
National Psoriasis Foundation, Board of the International Dermatology Outcome
Measures Group and president-elect of GRAPPA, the Board of the American Skin
Association, on the Medical and Scientific Board of the Lupus Foundation of
America. He is also the recent past president of the Medical Dermatology Society
and is president-elect of the Rheumatology-Dermatology Society. He is a
councilor for the International Eczema Council as well as the International
Psoriasis Council. He has served on multiple committees including the AAD
Guidelines Committee. Dr. Merola has published over 340 peer-reviewed
publications and received numerous awards for education, research and
mentorship.


PRESENTATIONS

Improving Outcomes in Patients with Psoriasis and Psoriatic Arthritis: A Focus
on Interleukin Inhibitors
Wednesday, Nov 13, 2024, 10:45 - 11:53am EST
Complex Dermatology Cases
Wednesday, Nov 13, 2024, 2:45 - 3:31pm EST
More Than Surface Level: The Role of Topical PDE-4 Inhibitors in the Treatment
of Atopic Dermatitis, Seborrheic Dermatitis, and Psoriasis
Friday, Nov 15, 2024, 11:50am - 12:50pm EST
Improving Outcomes in Patients with Psoriasis and Psoriatic Arthritis: A Focus
on Interleukin Inhibitors
Wednesday, May 8, 2024, 10:45am - 12pm EDT
Edit Joseph





CONNECT

 * Facebook
 * Linkedin
 * 


ABOUT

 * About Us
 * Contact Us
 * Privacy Policy


VISIT OUR OTHER BRANDS


VISIT OUR OTHER BRANDS

 * APP Institute | Dermatology
 * Autoimmune Learning Network
 * Dermatology Learning Network
 * The Dermatologist

© 2024 VRTX Virtual by HMP Global